Xconomy’s Digital Events →
Robert Gould talks being pitched about Epizyme: “it was a fundamental area of biology, a fundamental opportunity, particularly in the field of cancer.” He was named the company’s CEO in 2010.
Sponsored · Webinar
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Sponsored · Whitepaper
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
How a patient-centric, technology-driven approach can broaden access to research and reach patients regardless of geography, ethnicity, sex, or gender
© 2007-2022, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.